Portal Vein Embolization with Contralateral Application of Stem Cells Facilitates Increase of Future Liver Remnant Volume in Patients with Liver Metastases
Language English Country United States Media print-electronic
Document type Journal Article
PubMed
28091729
DOI
10.1007/s00270-017-1566-8
PII: 10.1007/s00270-017-1566-8
Knihovny.cz E-resources
- Keywords
- CT liver volumetry, Future liver remnant volume, Hematopoietic stem cells, Liver resection, Portal vein embolization,
- MeSH
- Hematopoietic Stem Cells MeSH
- Middle Aged MeSH
- Humans MeSH
- Liver Neoplasms diagnostic imaging secondary therapy MeSH
- Tomography, X-Ray Computed MeSH
- Prospective Studies MeSH
- Liver Regeneration * MeSH
- Aged MeSH
- Embolization, Therapeutic methods MeSH
- Hematopoietic Stem Cell Transplantation * MeSH
- Portal Vein * MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
OBJECTIVES: This study aimed to evaluate the progress of future liver remnant volume (FLRV) in patients with liver metastases after portal vein embolization (PVE) with the application of hematopoietic stem cells (HSCs) and compare it with a patients control group after PVE only. METHODS: Twenty patients (group 1) underwent PVE with contralateral HSC application. Subsequently, CT volumetry with the determination of FLRV was performed at weekly intervals, in total three weeks. A sample of twenty patients (group 2) who underwent PVE without HSC application was used as a control group. RESULTS: The mean of FLRV increased by 173.2 mL during three weeks after the PVE/HSC procedure, whereas by 98.9 mL after PVE only (p = 0.015). Furthermore, the mean daily growth of FLRV by 7.6 mL in group 1 was significantly higher in comparison with 4.1 mL in group 2 (p = 0.007). CONCLUSIONS: PVE with the application of HSC significantly facilitates growth of FLRV in comparison with PVE only. This method could be one of the new suitable approaches to increase the resectability of liver tumours.
References provided by Crossref.org
PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study